Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine 1B receptor antagonist elzasonan in humans

Drug Metabolism and Disposition

Volumn 38, Issue 11, 2010, Pages 1984-1999

  Kamel, Amin ^a,b   Obach, R Scott ^a,b   Colizza, Kevin ^a   Wang, Weiwei ^a   O'Connell, Thomas N ^a   Coelho Jr , Richard V ^a   Kelley, Ryan M ^a   Schildknegt, Klaas ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYELZASONAN; CARBON 14; DRUG METABOLITE; ELZASONAN; HYDROXYGLUCURONIDE; INDOLE; N DESMETHYL; N OXIDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EXCRETION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; ISOTOPE LABELING; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FECES; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; MORPHOLINES; PIPERAZINES; PROTEIN BINDING; RATS; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; TANDEM MASS SPECTROMETRY;

EID: 78049374628     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034595     Document Type: Article

References (34)

1. Argoti D, Liang L, Conteh A, Chen L, Bershas D, Yu CP, Vouros P, and Yang E (2005) Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem Res Toxicol 18:1537-1544.
2. Brandange S and Lindblom L (1979) Synthesis, structure and stability of nicotine Δ1′(5′)-iminium ion, an intermediary metabolite of nicotine Acta Chem Scand Ser B 33:187-191.
3. Byrd GD, Caldwell WS, Beck DJ, Kaminski DL, and Li AP (1994) Profile of nicotine metabolites from human hepatocytes, in Proceedings of the Sixth North American ISSX Meeting; 1994 October 23-27; Raleigh, NC. Abstract 173. International Society for the Study of Xenobiotics, Washington, DC.
4. Carlson TJ, Jones JP, Peterson L, Castagnoli N Jr, Iyer KR, and Trager WF (1995) Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the Δ1′,5-nicotinium ion. Drug Metab Dispos 23:749-756.
5. Cashman JR, Voelker T, Johnson R, and Janowsky A (2009) Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Biorg Med Chem 17:337-343.
6. Colizza K, Wang W, Davis J, and Kamel A (2008) Characterization of in vivo metabolites of the potent 5-HT1D receptor antagonist CP-448,187 in Sprague-Dawley rats by HPLC/RAM/ESI/MS/MS, in Proceedings of the 56th ASMS Conference on Mass Spectrometry and Allied Topics; 2008 June 1-8; Denver, Colorado. American Society for Mass Spectrometry, Santa Fe, NM.
7. Driscoll JP, Kornecki K, Wolkowski JP, Chupak L, Kalgutkar AS, and O'Donnell JP (2007) Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate. Chem Res Toxicol 20:1488-1997.
8. Gorrod JW and Aislaitner G (1994) The metabolism of alicyclic amines to reactive iminium ion intermediates. Eur J Drug Met Pharmacokinet 19:209-217.
9. 14C-sodium cyanide during microsomal oxidation. Adv Exp Med Biol 283:657-664.
10. Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413.
11. Hoag MK, Schmidt-Peetz M, Lampen P, Trevor A, and Castagnoli N Jr (1988) Metabolic studies on phencyclidine: characterization of a phencyclidine iminium ion metabolite. Chem Res Toxicol 1:128-131.
12. Hoag MK, Trevor AJ, Kalir A, and Castagnoli N Jr (1987) Phencyclidine iminium ion. NADPH-dependent metabolism, covalent binding to macromolecules, and inactivation of cytochrome(s) P-450. Drug Metab Dispos 15:485-490.
13. Hop CE, Wang Z, Chen Q, and Kwei G (1998) Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901-903.
14. Iverson S, Zahid N, and Uetrecht JP (2002) Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis. Chem Biol Interact 142:175-199. (Pubitemid 35232558)
15. Kamel A, Colizza K, and Wang W (2009) Characterization of the P450-isozyme(s) responsible for the formation of 5-OH-CP-448,187 (M2) and N-oxide-CP-448,187 (M10) in human liver microsomes by HPLC/ESI/MS/MS, in Proceedings of the 57th ASMS Conference on Mass Spectrometry and Allied Topics; 2009 May 31-June 4; Philadelphia. American Society for Mass Spectrometry, Santa Fe, NM.
16. Nassar AE, Bjorge SM, and Lee DY (2003) On-line liquid chromatography-accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identification in drug discovery and development. Anal Chem 75:785-790.
17. Obach RS and Dalvie DK (2006) Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase A, and cytochrome P450 enzymes. Drug Metab Dispos 34:1310-1316.
18. Obach RS and Van Vunakis H (1988) Non-metabolic covalent binding of nicotine-Δ1′(5′)-iminium ion to liver microsomes and sulfhydryl-containing polyamino acids. Biochem Pharmacol 37:4601-4604.
19. Olvey EL and Skrepnek GH (2008) The cost-effectiveness of sertraline in the treatment of depression. Expert Opin Pharmacother 9:2497-2508.
20. Ortiz de Montellano PR (1995) Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd ed, Plenum Press, New York.
21. Osawa Y and Coon MJ (1989) Selective mechanism-based inactivation of the major phenobarbital-inducible P-450 cytochrome from rabbit liver by phencyclidine and its oxidation product, the iminium compound. Drug Metab Dispos 17:7-13.
22. Overton M, Hickman JA, Threadgill MD, Vaughan K, and Gescher A (1985) The generation of potentially toxic, reactive iminium ions from the oxidative metabolism of xenobiotic N-alkyl compounds. Biochem Pharmacol 34:2055-2061.
23. Riad LE, Chan KK, and Sawchuk RJ (1991) Determination of the relative formation and elimination clearance of two major carbamazepine metabolites in humans: a comparison between traditional and pooled sample analysis. Pharm Res 8:541-543.
24. Roberts P, Kitteringham NR, and Park BK (1991) Species differences in the activation of mianserin to a cytotoxic metabolite. Drug Metab Dispos 19:841-843.
25. Roffey SJ, Obach RS, Gedge JI, and Smith DA (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17-43.
26. Sayre LM, Engelhart DA, Nadkarni DV, Babu MK, Klein ME, and McCoy G (1995) Haemoprotein-mediated metabolism of enamines and the possible involvement of one-electron oxidations. Xenobiotica 25:769-775.
27. Sayre LM, Engelhart DA, Nadkarni DV, Manoj Babu MK, Flammang AM, and McCoy GD (1997) The role of iminium-enamine species in the toxication and detoxication of cyclic tertiary amines. NIDA Res Monogr 173:106-127.
28. Sayre LM, Engelhart DA, Venkataraman B, Babu MK, and McCoy GD (1991) Generation and fate of enamines in the microsomal metabolism of cyclic tertiary amines. Biochem Biophys Res Commun 179:1368-1376.
29. 3H]nicotine to liver and lung microsomal macromolecules. Drug Metab Dispos 16:397-402.
30. Slassi A (2002) Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. Curr Top Med Chem 2:559-574.
31. Vickers S and Polsky SL (2000) The biotransformation of nitrogen containing xenobiotics to lactams. Curr Drug Metab 1:357-389.
32. Wang W, Colizza K, and Kamel A (2009) Characterization of in vivo metabolites of the potent 5-HT1D receptor antagonist CP-448,187 in mouse by HPLC/RAM/ESI/MS/MS, in Proceedings of the 57th ASMS Conference on Mass Spectrometry and Allied Topics; 2009 May 31-June 4; Philadelphia, PA. American Society for Mass Spectrometry, Santa Fe, NM.
33. Ward DP, Trevor AJ, Kalir A, Adams JD, Baillie TA, and Castagnoli N Jr (1982) Metabolism of phencyclidine. The role of iminium ion formation in covalent binding to rabbit microsomal protein. Drug Metab Dispos 10:690-695. (Pubitemid 13223708)
34. Williams DE, Shigenaga MK, and Castagnoli N Jr (1990) The role of cytochromes P-450 and flavin-containing monooxygenase in the metabolism of (S)-nicotine by rabbit lung. Drug Metab Dispos 18:418-428.